Sunday, September 11, 2016

BRIEF-Onxeo announces first outcomes of Livatag preclinical plan

* Livatag nanoformulation leads to increased exposure and preferential affinity for liver,

supporting current relive phase III study rationale

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)